Table 3.

Clinical characteristics of patients with de novo metastatic NPC according to risk after PCT

	Low-risk patients (n = 208)			High-risk patients (n = 294)
Characteristic	LRRT	Non-LRRT	P-value	LRRT	Non-LRRT	P-value
Total	165	43		150	144
Gender
Male	134 (81.2%)	34 (79.1%)	0.828	128 (85.3%)	121 (84.0%)	0.871
Female	31 (18.8%)	9 (20.9%)		22 (14.7%)	23 (16.0%)
Age (years)
≤ 47	94 (57.0%)	19 (44.2%)	0.169	77 (51.3%)	71 (49.3%)	0.816
> 47	71 (43.0%)	24 (55.8%)		73 (48.7%)	73 (50.7%)
T stage
T1	5 (3.0%)	0 (0.0%)	0.495*	6 (4.0%)	10 (6.9%)	0.458
T2	22 (13.3%)	4 (9.3%)		22 (14.7%)	15 (10.4%)
T3	83 (50.3%)	20 (46.5%)		71 (47.3%)	74 (51.4%)
T4	55 (33.3%)	19 (44.2%)		51 (34.0%)	45 (31.3%)
N stage
N0	9 (5.5%)	0 (0.0%)	0.362	4 (2.7%)	3 (2.1%)	0.452*
N1	33 (20.0%)	8 (18.6%)		29 (19.3%)	19 (13.2%)
N2	73 (44.2%)	18 (41.9%)		52 (34.7%)	59 (41.0%)
N3	50 (30.3%)	17 (39.5%)		65 (43.8%)	63 (43.8%)
Metastatic sites
Bone	99 (60.0%)	13 (30.2%)	< 0.001*	64 (42.7%)	50 (34.7%)	0.006
Lung	25(%15.2)	13 (30.2%)		15 (10.0%)	11 (7.6%)
Liver	9 (5.5%)	6 (14.0%)		14 (9.3%)	20 (13.9%)
Distant nodal	20 (12.1%)	0 (0.0%)		13 (8.7%)	2 (1.4%)
Multiple sites	12 (7.3%)	11 (25.6%)		44 (29.3%)	61 (42.4%)
PCT regimens
TPF	55 (33.3%)	10 (23.3%)	0.021	33 (22.0%)	32 (22.2%)	0.180
TP	46 (27.9%)	7 (16.3%)		39 (26.0%)	29 (20.1%)
PF	33 (20.0%)	16 (37.2%)		40 (26.7%)	42 (29.2%)
GP	4 (2.4%)	4 (9.3%)		5 (3.3%)	14 (9.7%)
Others	27 (16.4%)	6 (14.0%)		33 (22.0%)	27 (18.8%)

Abbreviations: LRRT locoregional radiotherapy, TPF cisplatin plus docetaxel plus 5-fluorouracil, TP cisplatin plus docetaxel, PF cisplatin plus 5-fluorouracil, GP cisplatin plus gemcitabine

P-value was calculated with the Pearson χ² test or Fisher’s exact test (*)